DWTX vs. XLO, CLNN, MRSN, SCYX, RNXT, ALXO, OKUR, ESLA, CLSD, and BTAI
Should you be buying Dogwood Therapeutics stock or one of its competitors? The main competitors of Dogwood Therapeutics include Xilio Therapeutics (XLO), Clene (CLNN), Mersana Therapeutics (MRSN), SCYNEXIS (SCYX), RenovoRx (RNXT), ALX Oncology (ALXO), OnKure Therapeutics (OKUR), Estrella Immunopharma (ESLA), Clearside Biomedical (CLSD), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry.
Dogwood Therapeutics vs. Its Competitors
Xilio Therapeutics (NASDAQ:XLO) and Dogwood Therapeutics (NASDAQ:DWTX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment and dividends.
Xilio Therapeutics has a beta of -0.15, indicating that its share price is 115% less volatile than the S&P 500. Comparatively, Dogwood Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500.
Dogwood Therapeutics has lower revenue, but higher earnings than Xilio Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Dogwood Therapeutics, indicating that it is currently the more affordable of the two stocks.
54.3% of Xilio Therapeutics shares are owned by institutional investors. Comparatively, 9.1% of Dogwood Therapeutics shares are owned by institutional investors. 6.3% of Xilio Therapeutics shares are owned by insiders. Comparatively, 3.9% of Dogwood Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Dogwood Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -374.79%. Dogwood Therapeutics' return on equity of 0.00% beat Xilio Therapeutics' return on equity.
In the previous week, Dogwood Therapeutics had 8 more articles in the media than Xilio Therapeutics. MarketBeat recorded 10 mentions for Dogwood Therapeutics and 2 mentions for Xilio Therapeutics. Dogwood Therapeutics' average media sentiment score of 0.09 beat Xilio Therapeutics' score of -0.75 indicating that Dogwood Therapeutics is being referred to more favorably in the news media.
Xilio Therapeutics presently has a consensus target price of $3.00, indicating a potential upside of 328.57%. Dogwood Therapeutics has a consensus target price of $10.00, indicating a potential upside of 102.63%. Given Xilio Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Xilio Therapeutics is more favorable than Dogwood Therapeutics.
Summary
Xilio Therapeutics and Dogwood Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.
Get Dogwood Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DWTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding DWTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dogwood Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DWTX) was last updated on 8/26/2025 by MarketBeat.com Staff
MarketBeat All Access